Hint mode is switched on Switch off
For swift navigation between sections

Organization: Novo Nordisk
LEI 549300DAQ1CVT6CXN342

Organization name
Novo Nordisk A/S
Country name
Denmark
Country of registration
Denmark
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
2,994 mln USD

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Novo Nordisk is a Denmark-based company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes and Biopharmaceuticals. Diabetes division offers a range of diabetes products, including modern insulins, Biopharmaceuticals division provides treatments for people with haemophilia, growth hormone deficiency and for women experiencing symptoms of menopause / 08.12

Awards

News

12/02/2024 Moody's Investors Service affirms Novo Nordisk at "A1" (LT- foreign currency credit rating); outlook stable
10/02/2024 Moody's affirms Novo Nordisk's A1 rating; outlook stable (Rating action commentary)
26/06/2023 S&P Global Ratings affirms Novo Nordisk at "AA-" (Local Currency LT credit rating); outlook stable
26/06/2023 S&P Global Ratings affirms Novo Nordisk at "AA-" (Foreign Currency LT credit rating); outlook stable
29/06/2022 S&P Global Ratings affirms Novo Nordisk at "AA-" (Local Currency LT credit rating); outlook stable
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    549300DAQ1CVT6CXN342
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000353278

Credit and ESG Ratings

Macroeconomic Indicators - Novo Nordisk

Registration is required to get access.